Clinical observation of gefitinib as a first-line therapy in sixty-eight patients with advanced NSCLC

Gao,Zhiqiang; Han,Baohui; Wang,Huimin; Shi,Chunlei; Xiong,Liwen; Gu,Aiqin

doi:10.3892/ol.2012.631

May 2012 Volume 3 Issue 5

Full Size Image

Journals

International Journal of Molecular Medicine

International Journal of Molecular Medicine is an international journal devoted to molecular mechanisms of human disease.

International Journal of Oncology

International Journal of Oncology is an international journal devoted to oncology research and cancer treatment.

Molecular Medicine Reports

Covers molecular medicine topics such as pharmacology, pathology, genetics, neuroscience, infectious diseases, molecular cardiology, and molecular surgery.

Oncology Reports

Oncology Reports is an international journal devoted to fundamental and applied research in Oncology.

Experimental and Therapeutic Medicine

Experimental and Therapeutic Medicine is an international journal devoted to laboratory and clinical medicine.

Oncology Letters

Oncology Letters is an international journal devoted to Experimental and Clinical Oncology.

Biomedical Reports

Explores a wide range of biological and medical fields, including pharmacology, genetics, microbiology, neuroscience, and molecular cardiology.

Molecular and Clinical Oncology

International journal addressing all aspects of oncology research, from tumorigenesis and oncogenes to chemotherapy and metastasis.

World Academy of Sciences Journal

Multidisciplinary open-access journal spanning biochemistry, genetics, neuroscience, environmental health, and synthetic biology.

International Journal of Functional Nutrition

Open-access journal combining biochemistry, pharmacology, immunology, and genetics to advance health through functional nutrition.

International Journal of Epigenetics

Publishes open-access research on using epigenetics to advance understanding and treatment of human disease.

Medicine International

An International Open Access Journal Devoted to General Medicine.

May 2012 Volume 3 Issue 5

Full Size Image

Article

Clinical observation of gefitinib as a first-line therapy in sixty-eight patients with advanced NSCLC

Authors:
- Zhiqiang Gao
- Baohui Han
- Huimin Wang
- Chunlei Shi
- Liwen Xiong
- Aiqin Gu
View Affiliations / Copyright

Affiliations: Department of Pulmonary Medicine, Chest Hospital Affiliated to Shanghai JiaoTong University, Shanghai 200030, P.R. China
Pages: 1064-1068
|
Published online on: March 5, 2012

https://doi.org/10.3892/ol.2012.631
Expand metrics +

Abstract

The aim of this study was to evaluate the efficacy and safety of gefitinib as a first-line therapy for advanced non-small cell lung cancer (NSCLC). Patients with advanced NSCLC who did not tolerate or who refused chemotherapy received 250 mg/day of gefitinib orally as first-line therapy. A total of 68 NSCLC patients were enrolled, and the overall response rate (RR) and disease controlled rate (DCR) with gefitinib treatment was 35.3 and 77.9%, respectively. The median progression-free survival (PFS) was 6.6 months and the median survival was 15.5 months. The median PFS of the adenocarcinoma patients and the non-smokers was significantly longer compared to that of the non-adenocarcinoma patients and the smokers (P<0.05). The median survival of the patients with Eastern Cooperative Oncology Group Performance Status (ECOG PS) 0-1 was significantly longer compared to that of the patients with PS ≥2 (P<0.05). The most common side effects of gefitinib treatment were mild rash and diarrhea. Therefore, first-line therapy with gefitinib is an effective and tolerable treatment regimen for advanced NSCLC.

View Figures

View References

1	Siegel R, Ward E, Brawley O and Jemal A: Cancer statistics: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J Clin. 61:212–236. 2011. View Article : Google Scholar : PubMed/NCBI
2	Giaccone G, Herbst RS, Manegold C, et al: Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III trial - INTACT 1. J Clin Oncol. 22:777–784. 2004. View Article : Google Scholar : PubMed/NCBI
3	Herbst RS, Giaccone G, Schiller JH, et al: Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial - INTACT 2. J Clin Oncol. 22:785–794. 2004. View Article : Google Scholar : PubMed/NCBI
4	Herbst RS, Prager D, Hermann R, et al: TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer. J Clin Oncol. 23:5892–5899. 2005. View Article : Google Scholar
5	Mok TS, Wu YL, Thongprasert S, et al: Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med. 361:947–957. 2009. View Article : Google Scholar : PubMed/NCBI
6	Eisenhauer EA, Therasse P, Bogaerts J, et al: New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 45:228–247. 2009. View Article : Google Scholar
7	Wiffen P, Mitchel M, Snelling M and Stoner N: Oxford Handbook of Clinical Pharmacy. Oxford University Press; New York: 2007
8	Gaughan EM and Costa DB: Genotype-driven therapies for non-small cell lung cancer: focus on EGFR, KRAS and ALK gene abnormalities. Ther Adv Med Oncol. 3:113–125. 2011. View Article : Google Scholar : PubMed/NCBI
9	Fukuoka M, Yano S, Giaccone G, et al: Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) [corrected]. J Clin Oncol. 21:2237–2246. 2003.
10	Kris MG, Natale RB, Herbst RS, et al: Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial. JAMA. 290:2149–2158. 2003. View Article : Google Scholar : PubMed/NCBI
11	Chang A, Parikh P, Thongprasert S, et al: Gefitinib (IRESSA) in patients of Asian origin with refractory advanced non-small cell lung cancer: subset analysis from the ISEL study. J Thorac Oncol. 1:847–855. 2006. View Article : Google Scholar : PubMed/NCBI
12	Lee J, Park K, Kim S, et al: A randomized phase III study of gefitinib versus standard chemotherapy (gemcitabine plus cisplatin) as a first-line treatment for never-smokers with advanced or metastatic adenocarcinoma of the lung. J Thorac Oncol. 4:S2832009.
13	Maemondo M, Inoue A, Kobayashi K, et al: Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med. 362:2380–2388. 2010. View Article : Google Scholar : PubMed/NCBI

Journals

International Journal of Molecular Medicine

International Journal of Oncology

Molecular Medicine Reports

Oncology Reports

Experimental and Therapeutic Medicine

Oncology Letters

Biomedical Reports

Molecular and Clinical Oncology

World Academy of Sciences Journal

International Journal of Functional Nutrition

International Journal of Epigenetics

Medicine International

Clinical observation of gefitinib as a first-line therapy in sixty-eight patients with advanced NSCLC

This article is mentioned in:

Abstract

Figure 1

Related Articles